Michael Snyderman presented his updated poster at MD Anderson last week for a conference on hematologic malignancies. Dr. Snyderman is an oncologist with CLL and CFS who believes that existing antiretrovirals should be fully investigated for the treatment of XMRV infection. His pioneering research should have significant overspill for understanding how to approach the treatment of CFS. He is exploring something which, even if partially successful, sheds light into the pathogenesis of human gammaretroviral infection. His early evidence that it is possible to effect the disease process even after neoplastic transformation has already occurred, is nothing short of astonishing.
Dr. Snyderman’s comments:
The CFS symptoms continue to be improved. The CD19 cells continue to decrease which means that the majority of the leukemia cells are responding. Thus some of the cancer measurements are favorable even if the trisomy12 story is incomplete. Cancer may be more difficult to treat than CFS but what we learn with cancer will help CFS. Several important scientists have become interested in XMRV and cancer and may sponsor studies that would benefit CFS patients.
Thank you, Dr. Snyderman.